Iovance Biotherapeutics is trading 4.17% higher at $10.62; the move appears to reflect a technical rebound or stock-specific trading, without a confirmed fresh catalyst. - It rebounded from September 23’s $10.19 close; no clear September 24 company-specific announcement explains the gain. - Earlier-September support included Amtagvi sales, profitability and upcoming lung-cancer data optimism, plus Barclays’ September 17 price-target hike to $15; none is new today. - Biotechnology stocks are down, while higher Treasury yields and rising oil prices pressure risk assets.